Possible Location: UK, Spain, Belgium, South Africa, Romania, Hungary, Ireland, France, Italy, Czech Republic, Bulgaria. This unique role within IQVIA lends itself to a technically minded person with strong communication skills and SDTM knowledge. Having experience
Pharmacometrics Support Programmer ICON is a global healthcare intelligence and clinical research organisation united by a mission to bring new medicines and treatments to patients faster. As a values-driven organisation, integrity, collaboration, agility, and inclusion are at the
The Clinical Data Manager performs activities pertaining to the conduct of Phase I-III clinical trials in accordance with ICH/Good Clinical Practices (GCP) and other relevant procedures and guidelines. The CDM ensures, from a data management perspective,
Senior Statistical Programmer I / II | Leading CRO | Home Based | UK | Permanent | Join a fast-growing, independent CRO providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device
Reading, Berkshire, United Kingdom Full time R Possible Location: UK, Spain, Belgium, South Africa, Romania, Hungary, Ireland, France, Italy, Czech Republic, Bulgaria. This unique role within IQVIA lends itself to a technically minded person with strong
Reading, Berkshire, United Kingdom Lisbon, Portugal Budapest, Hungary Barcelona, Spain Tartu, Estonia Prague, Czech Republic London, United Kingdom Madrid, Spain Full time R Overview IQVIA provides scientific services spanning clinical trials, real world evidence, and consulting
Pharmacometrics Support Programmer ICON plc is a world-leading healthcare intelligence and clinical research organization. Were proud to foster an inclusive environment driving innovation and excellence, and we welcome you to join us on our mission to shape the
Reading, Berkshire, United Kingdom Manchester, United Kingdom Livingston, West Lothian, United Kingdom London, United Kingdom Full time R The Clinical Data Manager performs activities pertaining to the conduct of Phase I-III clinical trials in accordance with